Standard BioTools Inc. (LAB) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$25.39M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$12.50M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$32.94M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$25.70M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$25.39M | (m) | $20.10M | (m) | $344.00K* | -$10.31M* | $9.57M | $1.98M | $16.39M | $90.00K |
| 2026-03-31 | Reported | (m) | -$12.50M | (m) | $21.15M | (m) | $570.00K | -$46.60M | $9.84M | $2.12M | $18.61M | $11.00K |
| 2025-09-30 | Reported | (m) | -$32.94M | (m) | $19.55M | (m) | $886.00K* | -$22.20M* | $10.07M | $6.36M | $26.59M | -$1.22M |
| 2025-06-30 | Reported | (m) | -$25.70M | (m) | $21.76M | (m) | $1.89M* | -$20.67M* | $11.13M | $6.22M | $28.11M | -$609.00K |
| 2025-03-31 | Reported | (m) | -$26.97M | (m) | $20.22M | (m) | $5.05M | -$30.28M | $9.17M | $5.44M | $29.82M | -$119.00K |
| 2024-09-30 | Reported | (m) | (m) | (m) | (m) | -103.42% | $2.25M* | -$27.87M* | $9.96M | $6.94M | $24.47M | $118.00K |
| 2024-06-30 | Reported | (m) | (m) | (m) | (m) | -117.40% | $1.94M* | -$39.05M* | $12.12M | $7.24M | $24.86M | $39.00K |
| 2024-03-31 | Reported | (m) | (m) | (m) | (m) | -120.75% | $781.00K | -$62.48M | $21.35M | $15.98M | $46.94M | $128.00K |
| 2023-12-31 | Reported | (m) | (m) | (m) | (m) | -70.91% | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | Reported | (m) | (m) | (m) | (m) | -67.75% | $905.00K* | -$11.41M* | $14.21M | $6.37M | $22.29M | $50.00K |
| 2023-06-30 | Reported | (m) | (m) | (m) | (m) | -49.96% | $838.00K* | -$9.33M* | $14.06M | $6.18M | $22.60M | $301.00K |
| 2023-03-31 | Reported | (m) | (m) | (m) | (m) | -51.48% | $1.01M | -$8.48M | $12.84M | $6.43M | $21.30M | $263.00K |
| 2022-09-30 | Reported | (m) | -$29.03M | (m) | $25.65M | (m) | $1.26M* | -$24.61M* | $16.43M | $8.49M | $26.34M | -$713.00K |
| 2022-06-30 | Reported | (m) | -$38.56M | (m) | $18.78M | (m) | $938.00K* | -$29.99M* | $14.35M | $12.61M | $30.08M | -$1.61M |
| 2022-03-31 | Reported | (m) | -$27.50M | (m) | $26.50M | (m) | $868.00K | -$15.59M | (m) | $8.87M | $30.88M | -$574.00K |
| 2021-09-30 | Reported | (m) | -$19.61M | (m) | $28.50M | (m) | $1.71M* | -$9.49M* | (m) | $9.21M | $24.07M | -$1.42M |
| 2021-06-30 | Reported | (m) | -$17.27M | (m) | $31.02M | (m) | $4.17M* | -$14.66M* | (m) | $9.44M | $24.25M | -$517.00K |
| 2021-03-31 | Reported | (m) | -$19.32M | (m) | $32.79M | (m) | $6.92M | -$12.90M | (m) | $10.75M | $27.61M | -$1.67M |
| 2020-09-30 | Reported | (m) | -$5.46M | (m) | $39.86M | (m) | $339.00K* | -$4.60M* | (m) | $8.13M | $22.66M | -$243.00K |
| 2020-06-30 | Reported | (m) | -$13.73M | (m) | $26.06M | (m) | $641.00K* | -$2.79M* | (m) | $8.45M | $20.62M | -$1.15M |
| 2020-03-31 | Reported | (m) | -$14.94M | (m) | $27.62M | (m) | $1.03M | -$4.29M | (m) | $8.70M | $22.70M | -$680.00K |
| 2019-09-30 | Reported | (m) | -$13.82M | (m) | $26.50M | (m) | $1.35M* | -$4.55M* | $12.46M | $7.13M | $20.73M | -$1.17M |
| 2019-06-30 | Reported | (m) | -$14.64M | (m) | $28.20M | (m) | $419.00K* | -$5.01M* | $12.83M | $7.87M | $22.13M | -$1.14M |
| 2019-03-31 | Reported | (m) | -$14.21M | (m) | $30.11M | (m) | $266.00K | -$20.13M | $13.12M | $8.37M | $22.82M | $42.00K |
| 2018-09-30 | Reported | (m) | -$11.63M | (m) | $28.96M | (m) | $198.00K* | -$4.06M* | $13.14M | $7.43M | $20.02M | -$780.00K |
| 2018-06-30 | Reported | (m) | -$12.79M | (m) | $26.43M | (m) | $77.00K* | -$4.32M* | $12.84M | $7.39M | $18.99M | -$204.00K |
| 2018-03-31 | Reported | (m) | -$12.63M | (m) | $25.25M | (m) | $77.00K | -$16.18M | $11.82M | $7.26M | $18.80M | -$1.18M |
| 2017-09-30 | Reported | (m) | -$15.60M | (m) | $24.75M | (m) | $554.00K* | -$7.98M* | (m) | $7.68M | $20.10M | -$735.00K |
| 2017-06-30 | Reported | (m) | -$16.49M | (m) | $23.91M | (m) | $142.00K* | -$8.29M* | (m) | $7.46M | $20.98M | -$827.00K |
| 2017-03-31 | Reported | (m) | -$17.54M | (m) | $25.53M | (m) | $692.00K | -$8.49M | (m) | $8.52M | $22.58M | -$1.78M |
| 2016-09-30 | Reported | (m) | -$18.48M | (m) | (m) | (m) | $1.71M* | -$13.26M* | (m) | $9.25M | $21.12M | -$309.00K |
| 2016-06-30 | Reported | (m) | -$18.14M | (m) | (m) | (m) | $1.52M* | -$7.35M* | (m) | $9.98M | $23.84M | -$1.02M |
| 2016-03-31 | Reported | (m) | -$18.87M | (m) | (m) | (m) | $1.14M | -$7.79M | (m) | $10.41M | $25.48M | -$762.00K |
| 2015-09-30 | Reported | (m) | -$7.80M | (m) | (m) | (m) | $235.00K* | -$12.70M* | (m) | $9.44M | $19.56M | -$362.00K |
| 2015-06-30 | Reported | (m) | -$14.66M | (m) | (m) | (m) | $1.40M* | -$7.83M* | (m) | $10.09M | $21.22M | -$266.00K |
| 2015-03-31 | Reported | (m) | -$14.00M | (m) | (m) | (m) | $909.00K | -$9.80M | (m) | $9.99M | $20.09M | -$643.00K |
| 2014-09-30 | Reported | (m) | -$13.05M | (m) | (m) | (m) | $1.36M* | -$8.86M* | (m) | $12.69M | $18.57M | -$716.00K |
| 2014-06-30 | Reported | (m) | -$12.38M | (m) | (m) | (m) | $2.75M* | $312.00K* | (m) | $11.37M | $18.66M | -$1.13M |
| 2014-03-31 | Reported | (m) | -$16.58M | (m) | (m) | (m) | $1.81M | -$10.55M | (m) | $7.65M | $15.26M | -$2.14M |
| 2013-09-30 | Reported | (m) | -$4.95M | (m) | (m) | (m) | $653.00K* | -$1.31M* | (m) | $5.00M | $12.10M | $42.00K |
| 2013-06-30 | Reported | (m) | -$3.99M | (m) | (m) | (m) | $214.00K* | -$2.64M* | (m) | $5.00M | $11.60M | $15.00K |
| 2013-03-31 | Reported | (m) | -$5.07M | (m) | (m) | (m) | $698.00K | -$884.00K | (m) | $4.20M | $11.15M | $38.00K |
| 2012-09-30 | Reported | (m) | -$3.91M | (m) | (m) | (m) | $382.00K* | -$3.34M* | (m) | $4.07M | $9.10M | $61.00K |
| 2012-06-30 | Reported | (m) | -$4.39M | (m) | (m) | (m) | $842.00K* | -$4.00M* | (m) | $3.99M | $9.42M | $1.00K |
| 2012-03-31 | Reported | (m) | -$6.28M | (m) | (m) | (m) | $397.00K | -$6.64M | (m) | $4.28M | $9.40M | $39.00K |
| 2011-09-30 | Reported | (m) | -$4.05M | (m) | (m) | (m) | $283.00K* | -$2.38M* | (m) | $3.29M | $8.05M | $20.00K |
| 2011-06-30 | Reported | (m) | -$6.65M | (m) | (m) | (m) | $494.00K* | -$11.68M* | (m) | $3.42M | $7.84M | $62.00K |
| 2011-03-31 | Reported | (m) | -$4.88M | (m) | (m) | (m) | $220.00K | -$1.23M | (m) | $3.22M | $7.44M | $48.00K |
| 2010-09-30 | Reported | (m) | -$3.10M | (m) | (m) | (m) | $472.00K* | -$3.22M* | (m) | $3.46M | $5.65M | -$13.00K |
| 2010-06-30 | Reported | (m) | -$4.23M | (m) | (m) | (m) | (m) | (m) | (m) | $3.45M | $5.90M | $141.00K |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$110.25M | (m) | $85.33M | (m) | $8.30M | -$74.34M | $42.79M | $25.99M | $109.86M | -$37.88M |
| 2024-12-31 | Reported | (m) | -$127.48M | (m) | $91.01M | (m) | $8.36M | -$143.45M | $46.13M | $28.83M | $103.06M | $542.00K |
| 2023-12-31 | Reported | (m) | (m) | (m) | (m) | -60.12% | $2.83M | -$43.29M | $55.89M | $25.95M | $87.54M | $452.00K |
| 2022-12-31 | Reported | (m) | (m) | (m) | (m) | -105.93% | $3.83M | -$89.37M | $60.90M | $37.38M | $102.28M | -$2.83M |
| 2021-12-31 | Reported | (m) | (m) | (m) | (m) | -49.20% | $13.26M | -$44.06M | (m) | $37.94M | $98.89M | -$4.42M |
| 2020-12-31 | Reported | (m) | -$51.04M | (m) | $138.14M | (m) | $12.72M | -$15.42M | (m) | $36.46M | $97.90M | -$1.08M |
| 2019-12-31 | Reported | (m) | -$51.84M | (m) | $117.24M | (m) | $2.53M | -$35.21M | $52.96M | $31.64M | $84.48M | -$1.92M |
| 2018-12-31 | Reported | (m) | -$48.16M | (m) | $112.96M | (m) | $372.00K | -$25.20M | $51.31M | $30.03M | $79.78M | -$2.41M |
| 2017-12-31 | Reported | (m) | -$58.36M | (m) | $101.94M | (m) | $1.57M | -$24.10M | $49.95M | $30.83M | $79.52M | -$3.26M |
| 2016-12-31 | Reported | (m) | -$73.19M | (m) | $104.45M | (m) | $5.07M | -$39.14M | $46.01M | $38.41M | $93.21M | -$4.19M |
| 2015-12-31 | Reported | (m) | -$50.16M | (m) | (m) | (m) | $3.98M | -$34.73M | (m) | $39.26M | $82.96M | -$1.48M |
| 2014-12-31 | Reported | (m) | -$51.84M | (m) | (m) | (m) | $7.40M | -$22.62M | (m) | $43.42M | $71.32M | -$4.88M |
| 2013-12-31 | Reported | (m) | -$18.65M | (m) | (m) | (m) | $3.45M | -$1.59M | (m) | $19.95M | $48.41M | $137.00K |
| 2012-12-31 | Reported | (m) | -$18.07M | (m) | (m) | (m) | $2.38M | -$17.48M | (m) | $16.60M | $38.48M | $136.00K |
| 2011-12-31 | Reported | (m) | -$18.57M | (m) | (m) | (m) | $1.68M | -$17.54M | (m) | $13.94M | $31.30M | $166.00K |
| 2010-12-31 | Reported | (m) | -$14.57M | (m) | (m) | (m) | $1.54M | -$11.51M | (m) | $13.01M | $23.55M | $83.00K |
| 2009-12-31 | Reported | (m) | -$18.04M | (m) | (m) | (m) | $799.00K | -$19.51M | (m) | $12.31M | $19.65M | -$50.00K |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |